Tessera Therapeutics received a grant from the Bill & Melinda Gates Foundation to support early‑stage research exploring genetic approaches aimed at a scalable HIV cure. Tessera said funding will back multiple programmatic avenues that leverage its genome‑writing platform to address HIV reservoirs and enable durable remission. The grant underscores continued philanthropic investment in curative strategies and backs efforts to translate advanced gene‑editing technologies into interventions that could be deployed at global scale.